Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
130.72
+3.72 (+2.93%)
Official Closing Price
Updated: 4:10 PM EDT, Apr 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
82
83
Next >
Amgen's Blockbuster Osteoporosis Drug Prolia Flagged With FDA Strictest Warning
January 19, 2024
FDA issues serious warning on Amgen's Prolia drug, highlighting increased risk of low calcium levels in specific patient groups.
Via
Benzinga
Exposures
Product Safety
Merck to Hold Fourth-Quarter and Full-Year 2023 Sales and Earnings Conference Call Feb. 1
January 19, 2024
From
Merck & Co., Inc.
Via
Business Wire
Why Is Cancer Focused Adagene Stock Plummeting Today?
January 17, 2024
Adagene presents results at ASCO 2024 Gastrointestinal Cancers Symposium. ADG126, combined with Merck's Keytruda, shows limited toxicity, sustained partial responses, and a 22% overall response rate in...
Via
Benzinga
The 3 Best Dividend Growth Stocks to Buy in January 2024
January 17, 2024
These are the best dividend growth stocks to buy as they represent companies with healthy free cash flow upside visibility.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
January 16, 2024
Via
Benzinga
Smart Money Is Betting Big In MRK Options
January 10, 2024
Via
Benzinga
Peering Into Merck & Co's Recent Short Interest
January 10, 2024
Via
Benzinga
Merck's Crown Jewel Cancer Drug Keytruda Scores FDA Approval For Third Indication In Cervical Cancer
January 16, 2024
FDA approves Merck's Keytruda for advanced cervical cancer. Keytruda plus chemoradiotherapy shows a 41% improvement in progression-free survival.
Via
Benzinga
Exposures
Product Safety
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
January 16, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
7 Healthcare Stocks Taking Medicine to the Next Level
January 14, 2024
With advances in technology potentially able to improve the human condition, these are the compelling healthcare stocks to consider.
Via
InvestorPlace
Demystifying Merck & Co: Insights From 9 Analyst Reviews
January 09, 2024
Via
Benzinga
These 9 Stocks Are Running To Start 2024
January 14, 2024
The S&P 500 is up just 0.2% in 2024. These stocks are off to a strong start.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer
January 12, 2024
From
Merck & Co., Inc.
Via
Business Wire
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review
January 12, 2024
The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut.
Via
Investor's Business Daily
Topics
ETFs
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Looks to Supercharge Reach, Impact of GLP-1 Agonists with Proprietary Drug-Delivery Solution
January 12, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
January 12, 2024
The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease.
Via
Investor's Business Daily
Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance
January 11, 2024
Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positioning themselves to tap into the
Via
Benzinga
AstraZeneca: Rebound in 2024 with double-digit earnings growth
January 11, 2024
AstraZeneca's stock rose 8.95% in the past month on a bullish outlook, driven by growing sales of cancer and diabetes drugs and a strategic acquisition
Via
MarketBeat
Exposures
COVID-19
The 3 Best Blue-Chip Stocks to Buy in January 2024
January 10, 2024
With a history of consistent shareholder returns, the best blue-chip stocks will reward patient investors in 2024.
Via
InvestorPlace
2024 Marks a New Era Of Pharmaceutical Innovation
January 09, 2024
With Covid-19 finally fading into history, the Covid-19 heroes, namely Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) were forced to redefine their business focus last year, and so, they turned...
Via
Benzinga
Exposures
COVID-19
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
January 08, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today?
January 08, 2024
Sunday, Exelixis Inc (NASDAQ: EXEL) provided financial guidance for fiscal year 2024 and delivered an
Via
Benzinga
Today Is Cancer-Focused Deals Day: Johnson & Johnson Scoops Up Ambrx Biopharma As Merck Boosts Cancer Portfolio With Harpoon Deal
January 08, 2024
Monday, Johnson & Johnson (NYSE: JNJ) has agreed to acquire Ambrx Biopharma Inc (NASDAQ: AMAM) in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billi
Via
Benzinga
Health Care Company Merck & Co Announces Acquisition of Harpoon Therapeutics
January 08, 2024
Via
Benzinga
Merck, the Dow's hottest stock, gets set to report Q4 financials
January 08, 2024
Up 5.7% year-to-date, pharmaceuticals - including MRK - are the best performing industry in the entire U.S. equity market, outpacing even biotech stocks.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
J&J, Merck, Boston Scientific Debut Trio Of Splashy Takeovers Topping $3 Billion In Value
January 08, 2024
The year's biggest medical conference kicked off with a melee of buyout news.
Via
Investor's Business Daily
Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs
January 08, 2024
Via
Investor Brand Network
Merck Stock Has Been A Laggard For Seven Months. Is It Staging A Comeback?
January 08, 2024
Shares shot 7% higher in the first week of 2024 as excitement grows for its late-stage pipeline.
Via
Investor's Business Daily
Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs
January 08, 2024
EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:PFE),(NYSE:MRK),(NASDAQ:AZN),(NYSE:NVO) EQNX::TICKER_END
Via
FinancialNewsMedia
Why Is Harpoon Therapeutics (HARP) Stock Up 111% Today?
January 08, 2024
Harpoon Therapeutics stock is rocketing higher on Monday as HARP investors react to Merck acquiring the company for $23 per share.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
82
83
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.